The U.S. STAR-D and already recruiting STAR-T randomized controlled pivotal trials are intended to establish DrugSorb-ATR as a single, easy-to-use solution for the reduction of perioperative bleeding in open heart surgery patients caused by the most widely prescribed next generation antiplatelet and anticoagulant drugs
90-day ICU Mortality was 27% with ECMO + CytoSorb in CTC Registry Data Presented on Day 1 of the International Symposium on Intensive Care and Emergency Medicine. For context, the Extracorporeal Life Support Organization COVID-19 ECMO Registry Reports 50% 90-day Mortality in North America with Standard ECMO Alone
Terri Anne Powers, IRC, experienced financial and communications professional, to strengthen and expand relationships with the investment and broader stakeholder community by building best-in-class investor relations and corporate communications function
Preliminary Full Year and Q4 2020 Product Sales were $39.5 million and $11.5 million, respectively, representing growth of 73% and 74%, respectively, over the corresponding prior periods. Cumulative CytoSorb treatments surpassed 121,000.
Seasoned sales veteran from Medtronic tasked to build and lead U.S. commercialization infrastructure as CytoSorbents sells CytoSorb under U.S. FDA Emergency Use Authorization for COVID-19 and leverages FDA Breakthrough Designation for potential future U.S. approval